文献速递浆细胞疾病

塞利尼索联合低剂量硼替佐米和地塞米松治疗复发或难治性多发性骨髓瘤患者

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
PubMed 文献 · Blood · 2018-10-23

这项研究评估塞利尼索联合低剂量硼替佐米和地塞米松(SVd)治疗复发或难治性多发性骨髓瘤的安全性、总缓解率(ORR)和推荐2期剂量(RP2D),共入组42例患者;全人群ORR为63%,蛋白酶体抑制剂(PI)非难治组为84%,PI难治组为43%;推荐的2期剂量为塞利尼索100毫克每周一次、硼替佐米1.3毫克/平方米每周一次共4周、地塞米松40毫克每周一次,每35天为一周期。

要点

  • 全人群ORR为63%,PI非难治组ORR为84%,PI难治组ORR为43%。
  • 全人群中位无进展生存期为9.0个月,PI非难治组为17.8个月,PI难治组为6.1个月。
  • 推荐2期剂量为塞利尼索100毫克每周一次、硼替佐米1.3毫克/平方米每周一次共4周、地塞米松40毫克每周一次,每35天为一周期。

核心结论

  • SVd治疗在复发或难治性多发性骨髓瘤患者(包括硼替佐米难治患者)中产生高缓解率,且未出现非预期副作用。

研究设计与样本

  • 研究入组42例复发或难治性多发性骨髓瘤患者,接受塞利尼索(60、80或100毫克口服)联合硼替佐米(1.3毫克/平方米皮下注射)和地塞米松(20毫克口服),每周一次或两次,21天或35天为一周期。
  • 患者既往治疗线数中位数为3(范围1-11),50%对PI难治。
  • 主要目标为确定安全性特征、总缓解率(ORR)和推荐2期剂量(RP2D)。

主要发现

  • 治疗相关3级或4级不良事件(发生率≥10%)包括血小板减少(45%)、中性粒细胞减少(24%)、乏力(14%)和贫血(12%)。
  • 周围神经病变发生率低(4例,10%),且分级≤2级。
  • 全人群ORR为63%,PI非难治组ORR为84%,PI难治组ORR为43%。
  • 全人群中位无进展生存期为9.0个月,PI非难治组为17.8个月,PI难治组为6.1个月。

关键数值与推荐

  • 推荐2期剂量(RP2D)为塞利尼索100毫克每周一次、硼替佐米1.3毫克/平方米每周一次共4周、地塞米松40毫克每周一次,每35天为一周期。

临床怎么用

  • SVd方案在复发或难治性多发性骨髓瘤患者(包括硼替佐米难治患者)中产生高缓解率,且未出现非预期副作用,推荐2期剂量如上。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Selinexor is an oral inhibitor of the nuclear export protein exportin 1. Preclinical studies demonstrated synergistic antimyeloma activity between selinexor and proteasome inhibitors (PI) through suppression of NF-κB signaling and nuclear retention of tumor suppressor proteins. We tested selinexor in combination with low-dose bortezomib and dexamethasone (SVd) for the treatment of relapsed or refractory multiple myeloma (MM). The primary objectives of this study were to determine the safety profile, overall response rate (ORR), and a recommended phase 2 dose (RP2D) of SVd. We enrolled 42 patients to receive selinexor (60, 80, or 100 mg orally) plus bortezomib (1.3 mg/m2 subcutaneously) and dexamethasone (20 mg orally) once or twice weekly in 21- or 35-day cycles. Patients had a median of 3 (range 1-11) prior lines of therapy, and 50% were refractory to a PI. Treatment-related grade 3 or 4 adverse events reported in ≥10% of patients were thrombocytopenia (45%), neutropenia (24%), fatigue (14%), and anemia (12%). Incidence (4 patients, 10%) and grade (≤2) of peripheral neuropathy were low. The ORR for the entire population was 63%: 84% ORR for PI nonrefractory and 43% for PI-refractory patients. The median progression-free survival for all patients was 9.0 months; 17.8 months for PI nonrefractory, and 6.1 months for PI refractory. SVd treatment produced high response rates in patients with relapsed or refractory MM, including borezomib-refractory MM, with no unexpected side effects. The RP2D is selinexor (100 mg once weekly), bortezomib (1.3 mg/m2 once weekly for 4 weeks), and dexamethasone (40 mg once weekly) per 35-day cycle. This trial was registered at www.clinicaltrials.gov as #NCT02343042.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Bahlis NJ, Sutherland H, White D, et al. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. Blood. 2018. PMID: 30352784. doi:10.1182/blood-2018-06-858852

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。